Group 1 - The Dividend Kings have shown strong performance in January 2025, achieving an average total return of 2.04% [1] - The performance of the Dividend Kings is noteworthy compared to the SPDR S&P 500 Trust ETF [1] Group 2 - The article reflects the author's personal investment positions in several companies, indicating a long position in shares of ABBV, ADP, GWW, HRL, JNJ, LOW, PEP, and SPGI [2]

Group 1 - AbbVie will participate in the TD Cowen's 45th Annual Health Care Conference on March 5, 2025, with management engaging in a fireside chat at 8:10 a.m. Central time [1] - A live audio webcast of the presentation will be available on AbbVie's Investor Relations website, with an archived version accessible later that day [1] Group 2 - AbbVie's mission focuses on discovering and delivering innovative medicines and solutions to address serious health issues and future medical challenges [2] - The company aims to make a significant impact in key therapeutic areas including immunology, oncology, neuroscience, and eye care, along with products in the Allergan Aesthetics portfolio [2]

Group 1 - The article discusses the potential benefits of investing in various income alternatives such as REITs, mREITs, Preferreds, BDCs, MLPs, and ETFs [1] - It highlights the positive feedback from users, with 438 testimonials, most of which are rated 5 stars, indicating a strong level of satisfaction with the research provided [1] Group 2 - There is a mention of a hypothetical scenario where two individuals relocate to a distraction-free tropical island for five years, emphasizing the importance of focus and environment in decision-making [1]

Core Insights - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceutical sectors [1] - The company emphasizes a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [1] - Allka Research is committed to simplifying investment strategies, making them accessible to both seasoned and novice investors [1] Company Mission - The mission of Allka Research is to empower individuals financially by sharing knowledge and insights through platforms like Seeking Alpha [1] - The company aims to provide thought-provoking analyses and informed perspectives to foster a community of informed investors [1] - Allka Research seeks to demystify investing, inspiring confidence in readers to navigate the financial markets intelligently [1]

Demographic Shift and Market Opportunities - The global population is aging rapidly, with the number of individuals aged 60 and older surpassing those under five for the first time in 2020, and by 2050, 80% of older adults will be in low- and middle-income countries [1] - The global geriatric care market was valued at approximately $1 trillion in 2022 and is projected to grow at a CAGR of 6.3% through 2030, driven by changing healthcare consumption patterns [2] Healthcare Sector Resilience - The healthcare sector remains resilient during economic downturns, ensuring consistent revenues due to stable demand for critical treatments and pharmaceuticals [5] Company Strategies and Innovations - AbbVie is expanding its focus on the senior demographic through strategic partnerships, including the acquisition of Aliada Therapeutics for Alzheimer's treatment and collaborations in oncology [6][7] - Amgen is emphasizing biopharmaceutical innovation to meet the health needs of aging societies, with a focus on osteoporosis and obesity treatments [9][10][11] - Stryker is making strategic investments in healthcare for seniors, enhancing capabilities in minimally invasive neurosurgery and improving patient care through medical data platforms [12][13][14] - Dexcom is expanding its continuous glucose monitoring systems to better serve seniors, ensuring accessibility through Medicare coverage and launching new products like Stelo for non-insulin users [15][16] Disease Prevalence and Treatment Development - The rise in life expectancy is leading to an increase in age-related diseases, prompting pharmaceutical companies to develop treatments for chronic conditions prevalent in older adults [3] - Companies leading in immunology, oncology, and neurodegenerative disease treatments are well-positioned for sustained growth [3] Technological Innovations in Elder Care - Innovations in medical technology and home care services are transforming elder care, with AI-driven diagnostics and home-based monitoring systems creating new revenue opportunities [4]

For any parent, funding their child's college education can be a very daunting prospect. According to a study by the enrollment-management consulting firm EAB , 60% of parents and guardians in the survey emphasized college costs being theirEver since I was eleven years old, I have been an ardent follower of the Stock Market and avid of learning new investing concepts. By providing fundamental analysis on dividend and growth equities across diverse sectors, I aim to guide new and inexperienced investors thri ...

Dividend stocks have been the backbone of market returns for over a century, contributing roughly two-thirds of total returns since 1900, according to a report by the Hartford Funds. Companies that consistently raise their dividends have been particularly strong performers, thanks to their ability to generate steady revenue growth and strong free cash flows across different market cycles.These dividend growers share several important characteristics that make them compelling long-term investments. They typi ...

My last analyses on Johnson & Johnson (NYSE: JNJ ) and AbbVie (NYSE: ABBV ) were both published before the release of their earnings. Furthermore, both articles placed an emphasis on dividends. More specifically, my As you can tell, our core style is to provide actionable and unambiguous ideas from our independent research. If your share this investment style, check out Envision Early Retirement. It provides at least 1x in-depth articles per week on such ideas.We have helped our members not only to beat S&P ...

Last August, I wrote an article arguing that AbbVie (NYSE: ABBV ) appeared overbought and ripe for a short-term period of moving sideways, or even testing support. In particular, I proposed that ABBV was still a good company, but that share performanceZvi provides advisory services to companies, trusts, and individuals, including consulting expert services regarding retirement and estate planning. Zvi is admitted to practice law in the state of New York, where he offers cash management, Bitcoin, and Trust P ...

Business Operations - AbbVie operates as a single global business segment focused on innovative medicines and therapies, enabling resource allocation and performance assessment on a global basis[15]. - AbbVie maintains a global corporate administrative staff to support its comprehensive research, development, and commercialization efforts[15]. - AbbVie utilizes a combination of dedicated and regional commercial resources, focusing on securing prescriptions from healthcare providers[42]. - The company engages in various arrangements, including acquisitions and licensing, to enhance its product development and market presence[63]. Product Portfolio - AbbVie's immunology portfolio includes Humira, Skyrizi, and Rinvoq, addressing various autoimmune diseases across North America, the European Union, and Japan[16][18][20]. - Humira is approved for multiple conditions, including rheumatoid arthritis and Crohn's disease, and is sold in numerous markets worldwide, including Japan, China, and Brazil[16][18]. - Skyrizi is an IL-23 inhibitor approved for moderate to severe plaque psoriasis and ulcerative colitis, administered via subcutaneous injection or IV infusion[18][19]. - Rinvoq is a once-daily JAK inhibitor approved for several inflammatory diseases, including rheumatoid arthritis and atopic dermatitis, with a presence in multiple global markets[20][22]. - AbbVie's oncology products include Imbruvica and Venclexta, targeting complex blood cancers, with Imbruvica being one of the first therapies to receive multiple FDA designations[23][24]. - The aesthetics portfolio includes Botox Cosmetic and the Juvederm Collection, which hold market-leading positions in the U.S. and key global markets[27][28]. - AbbVie's neuroscience products, such as Vraylar and Ubrelvy, address difficult-to-treat neurologic diseases and are approved in various markets[30][33]. - Eye care products like Ozurdex and Lumigan are designed to address visual impairment and elevated intraocular pressure, available in the U.S. and numerous international markets[36][38]. - AbbVie's key products include treatments for hepatitis C, metabolic and hormone products, and endocrinology products for various conditions[39]. - Mavyret is approved for treating chronic HCV genotype 1-6 infection in patients aged 12 and older, with specific indications for those previously treated with certain HCV inhibitors[39]. - Creon is a pancreatic enzyme therapy for exocrine pancreatic insufficiency, marketed only in the United States[40]. - Linzess is used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation, marketed as Linzess in the U.S. and Constella outside[41]. - AbbVie's medical device products, including breast implants, are primarily regulated as Class III medical devices, requiring extensive regulatory approval[97]. Research and Development - AbbVie invests significantly in research and development, focusing on compounds for complex, life-threatening diseases[66]. - The research and development process typically takes 8 to 12 years, with no guarantee of regulatory approval for new drugs[68]. - AbbVie collaborates with third parties, including biotechnology companies and academic institutions, to enhance its treatment portfolio[66]. - Regulatory approval in the U.S. requires substantial effort and financial resources, including successful completion of preclinical tests and clinical trials[70]. - Compliance with regulatory requirements is ensured through inspections by the FDA and other authorities, with potential consequences for non-compliance[71]. Market Environment - AbbVie faces significant competition from other pharmaceutical and biotechnology companies, particularly in immunology and oncology products[46]. - Humira faces direct biosimilar competition globally, impacting AbbVie's revenue from biologic products[48]. - AbbVie anticipates ongoing pricing pressures from insurers and providers, particularly in the U.S. and other countries[84]. - The Inflation Reduction Act of 2022 mandates government-set prices for select high-expenditure Medicare drugs starting in 2026, impacting revenue[88]. - In the European Union, pricing of pharmaceutical products is regulated, affecting market access and reimbursement[91]. - Japan's National Health Insurance system sets drug prices and mandates price cuts every two years, influencing product reimbursement[93]. Financial and Operational Insights - AbbVie's capital expenditures for pollution control in 2024 were approximately $13 million, with estimated operating expenditures of $35 million[103]. - The company employed approximately 55,000 employees in over 70 countries as of January 31, 2025[105]. - AbbVie has approximately $15.2 billion in foreign currency forward exchange contracts outstanding as of December 31, 2024, with a potential $1.5 billion decrease in fair value if there is a 10% appreciation in the underlying currencies[318]. - An increase in interest rates of 100 basis points would adversely impact the fair value of AbbVie's interest rate swap contracts by approximately $140 million[320]. - The company estimates that a 100 basis point increase in long-term interest rates would decrease the fair value of long-term debt by $4.6 billion[320]. - AbbVie has designated €3.1 billion in senior Euro notes as hedges of its net investments in certain foreign subsidiaries[319]. Corporate Responsibility and Employee Engagement - The company believes its operations comply with environmental protection laws, and it has ongoing remediation activities related to Superfund sites[104]. - AbbVie invests in employee development through competitive compensation and benefits, including health promotion programs and financial wellness support[107]. - The company emphasizes diversity and inclusion, conducting annual pay equity analyses to ensure equal opportunity for all employees[111].